Methylene blue administration in the compound 48/80-induced anaphylactic shock. Hemodynamic study in pigs;Administração de azul de metileno no choque anafilático induzido por composto 48/80. Estudo hemodinâmico em suínos

Acta Cirurgica Brasileira

Volumn 26, Issue 6, 2011, Pages 481-489

  Menardi, Antonio Carlos ^a   Capellini, Verena Kise ^a   Celotto, Andrea Carla ^a   Albuquerque, Agnes Afrodite Sumarelli ^a   Viaro, Fernanda ^a   Vicente, Walter Vilella A ^a   Rodrigues, Alfredo José ^a   Evora, Paulo Roberto Barbosa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anaphylaxis; Guanylate Cyclase. Swine; Methylene Blue; Nitric Oxide

Indexed keywords

COMPOUND 48-80; METHYLENE BLUE;

ANAPHYLACTIC SHOCK; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL VENOUS PRESSURE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; HEART OUTPUT; HEMODYNAMICS; LUNG ARTERY PRESSURE; LUNG CAPILLARY PRESSURE; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; SWINE; SYSTEMIC VASCULAR RESISTANCE;

ANAPHYLAXIS; ANIMALS; BLOOD PRESSURE; CARDIAC OUTPUT; DISEASE MODELS, ANIMAL; FEMALE; HEMODYNAMICS; METHYLENE BLUE; P-METHOXY-N-METHYLPHENETHYLAMINE; RANDOM ALLOCATION; SWINE; TIME FACTORS; VASCULAR RESISTANCE;

EID: 82355164455     PISSN: 01028650     EISSN: 16782674     Source Type: Journal    
DOI: 10.1590/S0102-86502011000600013     Document Type: Article

References (33)

1. Nava E, Palmer RM, Moncada S. Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet. 1991;21-28;338:1555-7.
2. Paya D, Gray GA, Stoclet JC. Effects of methylene blue on blood pressure and reactivity to norepinephrine in endotoxemic rats. J Cardiovasc Pharmacol. 1993;21:926-30.
3. Evora PRB, Seccombe JF, Pearson PJ, Schaff HV. O papel do óxido nítrico e perspectivas terapêuticas na sepse bacteriana. Rev Bras Terap Intens. 1994;6:105-7.
4. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res. 1994;28:34-9.
5. Daemen-Gubbels CR, Groeneveld PH, Groeneveld AB, van Kamp GJ, Bronsveld W, Thijs LG. Methylene blue increases myocardial function in septic shock. Crit Care Med. 1995;23:1363-70.
6. Keaney JF Jr, Puyana JC, Francis S, Loscalzo JF, Stamler JS, Loscalzo J. Methylene blue reverses endotoxin-induced hypotension. Circ Res. 1994;74:1121-5.
7. Marczin N, Tekeres M, Salzman AL, Szabo C. Methylene blue infusion in septic shock. Crit Care Med. 1995;23:1936-8.
8. Mayer J, Hajek R, Vorlicek J, Tomiska M. Sepsis and septic shock. I. Definitions and pathophysiology. Support Care Cancer. 1995;3:106-10.
9. Preiser JC, Lejeune P, Roman A, Carlier E, De Backer D, Leeman M, Kahn RJ, Vicent JL. Methylene blue administration in septic shock: a clinical trial. Crit Care Med. 1995;23:259-64.
10. Schneider F. Methylene blue infusion in septic shock. Crit Care Med. 1995;23:1935-6.
11. Zhang H, Rogiers P, Preiser JC, Spapen H, Manikis P, Metz G, Vicent JL. Effects of methylene blue on oxygen availability and regional blood flow during endotoxic shock. Crit Care Med. 1995;23:1711-21.
12. Osada S, Ichiki H, Oku H, Ishiguro K, Kunitomo M, Semma M. Participation of nitric oxide in mouse anaphylactic hypotension. Eur J Pharmacol. 1994;252:347-50.
13. Mitsuhata H, Shimizu R, Yokoyama MM. Role of nitric oxide in anaphylactic shock. J Clin Immunol. 1995;15:277-83.
14. Mitsuhata H, Takeuchi H, Saitoh J, Hasome N, Horiguchi Y, Shimizu R. An inhibitor of nitric oxide synthase, N omega-nitro-L-argininemethyl ester, attenuates hypotension but does not improve cardiac depression in anaphylaxis in dogs. Shock. 1995;3:447-54.
15. Evora PR, Ribeiro PJ, de Andrade JC. Methylene blue administration in SIRS after cardiac operations. Ann Thorac Surg. 1997;63:1212-3.
16. Evora PR, Roselino CH, Schiaveto PM. Methylene blue in anaphylactic shock. Ann Emerg Med. 1997;30:240.
17. Evora PRB, Roselino CH, Schiavetto PM. Utilização do azul de metileno no tratamento do choque anafilático. Uma proposição clínica e apresentação de três casos. Rev Bras Terap Intens. 1997;9:126-31.
18. Buzato MA, Viaro F, Piccinato CE, Evora PR. The use of methylene blue in the treatment of anaphylactic shock induced by compound 48/80: experimental studies in rabbits. Shock. 2005;23:582-7.
19. Bellou A, Lambert H, Gillois P, Montemont C, Gerard P, Vauthier E, Sainte-Laudy J, Longrois D, Guéant JL, Mallié JP. Constitutive nitric oxide synthase inhibition combined with histamine and serotonin receptor blockade improves the initial ovalbumin-induced arterial hypotension but decreases the survival time in brown norway rats anaphylactic shock. Shock. 2003;19:71-8.
20. Cauwels A, Janssen B, Buys E, Sips P, Brouckaert P. Anaphylactic shock depends on PI3K and eNOS-derived NO. J Clin Invest. 2006;116:2244-51.
21. Evora PR, Oliveira Neto AM, Duarte NM, Vicente WV. Methylene blue as treatment for contrast medium-induced anaphylaxis. J Postgrad Med. 2002;48:327.
22. Zwadlo-Klarwasser G, Braam U, Muhl-Zurbes P, Schmutzler W. Macrophages and lymphocytes: alternative sources of histamine. Agents Actions. 1994;41:C99-100.
23. Foldes A, Nemethy Z, Szalay O, Kovacs KJ. Anaphylactoid reactions activate hypothalamo-pituitary-adrenocortical axis: comparison with endotoxic reactions. Brain Res Bull. 2000;52:573-9.
24. Gomes JC, Antonio A. Effects of compound 48/80 on the guinea-pig isolated heart: a comparison with the in vitro cardiac anaphylaxis. Pharmacol Res Commun. 1981;13:873-90.
25. Amir S, English AM. An inhibitor of nitric oxide production, NGnitro-L-arginine-methyl ester, improves survival in anaphylactic shock. Eur J Pharmacol. 1991;203:125-7.
26. Takano H, Liu W, Zhao Z, Cui S, Zhang W, Shibamoto T. N(G)-nitro-L-arginine methyl ester, but not methylene blue, attenuates anaphylactic hypotension in anesthetized mice. J Pharmacol Sci. 2007;104:212-7.
27. Alexander JH, Reynolds HR, Stebbins AL, Dzavik V, Harrington RA, Van de Werf F, Hockman JS. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2000;297:1657-66.
28. Del Duca D, Sheth SS, Clarke AE, Lachapelle KJ, Ergina PL. Use of methylene blue for catecholamine-refractory vasoplegia from protamine and aprotinin. Ann Thorac Surg. 2009;87:640-2.
29. Andrade JCS, Batista Filho ML, Evora PRB, Tavares JR, Buffolo E, Ribeiro EE, Silva LA Teles CA, Petrizzo A, Barata Filho VV, Duprat R. Utilização do azul de metileno no tratamento da síndrome vasoplégica após cirurgia cardíaca. Rev Bras Cir Cardiovasc. 1996;11:107-14.
30. Evora PR. Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock? J Thorac Cardiovasc Surg. 2000;119:632-4.
31. Rodrigues JM, Pazin Filho A, Rodrigues AJ, Vicente WV, Evora PR. Methylene blue for clinical anaphylaxis treatment: a case report. Sao Paulo Med J. 2007;125:60-2.
32. Stocche RM, Garcia LV, Reis MP, Klamt JG, Evora PR. Methylene blue to treat anaphylaxis during anesthesia: case report. Rev Bras Anestesiol. 2004;54:809-14.
33. Oliveira Neto AM, Duarte NM, Vicente WV, Viaro F, Evora PR. Methylene blue: an effective treatment for contrast medium-induced anaphylaxis. Med Sci Monit. 2003;9:CS102-6.